IL-4 and TNF-α polymorphisms are associated with risk of multiple superficial tumors or carcinoma in situ development

Luís Lima, Joana Silva, Teresina Amaro, António Morais, Carlos Lopes, Rui Medeiros, Paula A. Videira, Lúcio Santos

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: This study evaluates the influence of clinicopathological characteristics, bacillus Calmette-Guérin (BCG) therapeutic schedule [maintenance (mBCG) or induction (iBCG)], and TNF-α and IL-4 polymorphisms on the outcome of non-muscle-invasive bladder cancer patients treated with BCG. Material and Methods: DNA was extracted from 125 bladder cancer patients treated with BCG; TNF-308G/A and IL4-590C/T polymorphisms were genotyped. Results: The TNF-308A allele carriers had an increased risk of developing multiple tumors (OR: 2.80, p = 0.031). However, IL4-590 T carriers also had an increased risk of developing multiple and carcinoma in situ tumors (OR: 2.52, p = 0.033). For these polymorphisms, no association was found with BCG treatment outcome. When treated with iBCG, patients with multiple tumors had shorter recurrence-free survival (RFS) compared with those with a single tumor (p = 0.004); nevertheless, patients with multifocal tumors have improved RFS when treated with mBCG. Conclusions: Overall, the results suggest that multiple tumors and/or carcinoma in situ development are associated with the IL4-590C/T and TNF-308G/A polymorphisms, and emphasize the effectiveness of the mBCG schedule.

Original languageEnglish
Pages (from-to)457-463
Number of pages7
JournalUrologia Internationalis
Volume87
Issue number4
DOIs
Publication statusPublished - Dec 2011

Keywords

  • Bacillus Calmette-Guérin
  • Bladder cancer
  • Genetic polymorphisms
  • Multifocality

Fingerprint Dive into the research topics of 'IL-4 and TNF-α polymorphisms are associated with risk of multiple superficial tumors or carcinoma in situ development'. Together they form a unique fingerprint.

  • Cite this